BiondVax Pharmaceuticals Ltd. [NASDAQ: BVXV] gained 15.03% on the last trading session, reaching $3.75 price per share at the time. The company report on October 23, 2020 that /C O R R E C T I O N — BiondVax Pharmaceuticals Ltd./.
In the news release, BiondVax Announces Topline Results from Phase 3 Clinical Trial of the M-001 Universal Influenza Vaccine Candidate, issued Oct. 23, 2020 by BiondVax Pharmaceuticals Ltd. over PR Newswire, we are advised by the company that the Forward Looking Statements were not included. The complete, corrected release follows:.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a pioneer in the development of a universal flu vaccine designed to provide protection against current, future, seasonal and pandemic influenza, announced topline data from the Company’s pivotal, phase 3 clinical trial of M-001 as a standalone universal flu vaccine candidate.
BiondVax Pharmaceuticals Ltd. represents 10.84 million in outstanding shares, while the company has a total market value of $43.73 million with the latest information. BVXV stock price has been found in the range of $3.20 to $3.86.
If compared to the average trading volume of 1.21M shares, BVXV reached a trading volume of 2216626 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BiondVax Pharmaceuticals Ltd. [BVXV]:
The Average True Range (ATR) for BiondVax Pharmaceuticals Ltd. is set at 0.33
Trading performance analysis for BVXV stock
BiondVax Pharmaceuticals Ltd. [BVXV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.97. With this latest performance, BVXV shares dropped by -3.60% in over the last four-week period, additionally sinking by -92.23% over the last 6 months – not to mention a drop of -66.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BVXV stock in for the last two-week period is set at 48.47, with the RSI for the last a single of trading hit 65.26, and the three-weeks RSI is set at 37.91 for BiondVax Pharmaceuticals Ltd. [BVXV]. The present Moving Average for the last 50 days of trading for this stock 3.15, while it was recorded at 3.33 for the last single week of trading, and 21.42 for the last 200 days.
BiondVax Pharmaceuticals Ltd. [BVXV]: A deeper dive into fundamental analysis
Return on Total Capital for BVXV is now -121.92, given the latest momentum, and Return on Invested Capital for the company is -170.86. Additionally, BVXV Total Debt to Total Capital is recorded at 198.22, with Total Debt to Total Assets ending up at 113.42.
Reflecting on the efficiency of the workforce at the company, BiondVax Pharmaceuticals Ltd. [BVXV] managed to generate an average of -$1,225,864 per employee.BiondVax Pharmaceuticals Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.50 and a Current Ratio set at 6.50.
BiondVax Pharmaceuticals Ltd. [BVXV]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, BiondVax Pharmaceuticals Ltd. posted -2.04/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -10,100.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BVXV.
An analysis of insider ownership at BiondVax Pharmaceuticals Ltd. [BVXV]
There are presently around $2 million, or 4.10% of BVXV stock, in the hands of institutional investors. The top three institutional holders of BVXV stocks are: IBEX INVESTORS LLC with ownership of 322,413, which is approximately -1.845% of the company’s market cap and around 37.10% of the total institutional ownership; MORGAN STANLEY, holding 48,666 shares of the stock with an approximate value of $0.16 million in BVXV stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $65000.0 in BVXV stock with ownership of nearly New of the company’s market capitalization.
Positions in BiondVax Pharmaceuticals Ltd. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 12 institutional holders increased their position in BiondVax Pharmaceuticals Ltd. [NASDAQ:BVXV] by around 108,757 shares. Additionally, 10 investors decreased positions by around 79,789 shares, while 1 investors held positions by with 276,400 shares. The mentioned changes placed institutional holdings at 464,946 shares, according to the latest SEC report filing. BVXV stock had 9 new institutional investments in for a total of 61,440 shares, while 6 institutional investors sold positions of 68,011 shares during the same period.